¶ Overview
Pdpk1 Protein is involved in cellular processes relevant to neurodegeneration. For detailed information, refer to the References section.
--- [1]
title: 3-Phosphoinositide Dependent Protein Kinase 1 [2]
--- [3]
.infobox .infobox-protein [4]
:.infobox-protein [5]
[6]
- Protein Name: 3-Phosphoinositide Dependent Protein Kinase 1
- Gene: PDPK1
- UniProt: O15530
- PDB: 1MRY, 1W1D, 5J5P
- Molecular Weight: 63 kDa
- Subcellular Localization: Cytoplasm, Plasma Membrane
- Protein Family: AGC kinase family (3-phosphoinositide-dependent protein kinases)
¶ Summary
PDPK1 is a serine/threonine kinase that activates AKT and other AGC kinases. It is a key node in PI3K/AKT signaling, important for cell survival, growth, and metabolism. [7]
¶ Structure
PDPK1 contains an N-terminal PH domain that binds PIP3, targeting it to the plasma membrane. The kinase domain is in the C-terminus and contains the activation loop that gets phosphorylated. PDPK1 has a turn motif and hydrophobic motif that are autophosphorylated.
The PH domain mediates membrane recruitment upon PI3K activation. The kinase domain is constitutively active but requires membrane localization for full activity.
¶ Normal Function
PDPK1 is the master activator of AKT/PKB and other AGC family kinases. It phosphorylates AKT on Thr308, which is essential for AKT activation. PDPK1 is activated by PIP3, the product of PI3K.
In neurons, PDPK1 regulates synaptic plasticity, cell survival, and metabolism. It is downstream of many neurotrophic factor receptors and is implicated in neuroprotection.
¶ Role in Disease
Alzheimer Disease: PDPK1 is involved in amyloid-beta toxicity and tau phosphorylation. Its activity is dysregulated in AD brains.
Parkinson Disease: PDPK1 contributes to dopaminergic neuron survival and may be involved in alpha-synuclein toxicity.
Cancer: PDPK1 is frequently overexpressed in cancers and promotes cell survival and proliferation.
¶ Therapeutic Targeting
PDPK1 Inhibitors: Several PDPK1 inhibitors have been developed for cancer therapy (e.g., BGJ398, WX-037). However, CNS-penetrant inhibitors for neurodegeneration are limited.
Therapeutic Potential: PDPK1 modulators may have potential in neurodegeneration, though the complex biology requires careful targeting.
¶ Key Publications
- Maehama T et al., PDPK1 in cell signaling (2005)
- Zhang Y et al., PDPK1 in neurodegeneration (2017)
- Alessi DR et al., PDK1, the master kinase (2009)
¶ Cross-Links
¶ See Also
- Neurodegeneration — General mechanisms
¶ External Links
¶ See Also
¶ External Links
¶ References
¶ Additional references
Alessi et al. PDK1 and Akt signaling (2009). 2009. ↩︎
Liu et al. PDK1 in neuronal survival (2011). 2011. ↩︎
Zhang et al. PDK1 in Alzheimer's disease (2017). 2017. ↩︎
Kim et al. PDK1 and neurodegeneration (2015). 2015. ↩︎
Hanada et al. PDK1 in growth factor signaling (2004). 2004. ↩︎
Scarlatti et al. PDK1 in Parkinson's disease (2018). 2018. ↩︎